Abstract
There were 80 patients with measurable metastatic or unresectable pancreatic cancer randomly assigned to treatment with either DHAD, VP-16, aclacinomycin, or spirogermanium. There were no complete or partial responses. Two deaths from leukopenia occurred in patients treated with DHAD. One patient receiving spirogermanium experienced a seizure. No other life-threatening toxicities occurred. Maximal toxicities were not significantly more frequent with any treatment group. Median survival was 10 weeks, and median time to progression was only 6 weeks, with no difference among these four therapies.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Randomized Controlled Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Aclarubicin / adverse effects
-
Aclarubicin / analogs & derivatives
-
Aclarubicin / therapeutic use
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / secondary
-
Adjuvants, Immunologic / therapeutic use
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Etoposide / adverse effects
-
Etoposide / therapeutic use
-
Female
-
Humans
-
Male
-
Mitoxantrone / adverse effects
-
Mitoxantrone / therapeutic use
-
Organometallic Compounds / adverse effects
-
Organometallic Compounds / therapeutic use
-
Pancreatic Neoplasms / drug therapy*
-
Pancreatic Neoplasms / mortality
-
Spiro Compounds / adverse effects
-
Spiro Compounds / therapeutic use
-
Survival Rate
Substances
-
Adjuvants, Immunologic
-
Antineoplastic Agents
-
Organometallic Compounds
-
Spiro Compounds
-
aclacinomycins
-
spirogermanium
-
Etoposide
-
Aclarubicin
-
Mitoxantrone